In today’s podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of low-dose rivaroxaban in peripheral artery disease after revascularization.

Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca

This podcast from NEJM Resident 360 takes a deep dive into key topics with expert clinicians and educators. As we explore the details of pathophysiology and critique the evidence behind clinical practice, these conversations are intended to give you better understanding of the topic and greater confidence when treating your patients.

Share Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca

Sign up to save your podcasts

Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca

Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca

More shows like Curbside Consults

NEJM Interviews

NEJM Journal Watch Podcasts: Clinical Conversations

NEJM This Week

JAMA Clinical Reviews

The Curbsiders Internal Medicine Podcast

Leadership Conversations

Core IM | Internal Medicine Podcast

Run the List

NEJM AI Grand Rounds

Intention to Treat

Not Otherwise Specified